[go: up one dir, main page]

WO2012005709A3 - Composition pharmaceutique comprenant du valsartan - Google Patents

Composition pharmaceutique comprenant du valsartan Download PDF

Info

Publication number
WO2012005709A3
WO2012005709A3 PCT/TR2011/000168 TR2011000168W WO2012005709A3 WO 2012005709 A3 WO2012005709 A3 WO 2012005709A3 TR 2011000168 W TR2011000168 W TR 2011000168W WO 2012005709 A3 WO2012005709 A3 WO 2012005709A3
Authority
WO
WIPO (PCT)
Prior art keywords
valsartan
pharmaceutical composition
granules
pharmaceutically acceptable
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/TR2011/000168
Other languages
English (en)
Other versions
WO2012005709A2 (fr
Inventor
Mahmut Bilgic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2012005709A2 publication Critical patent/WO2012005709A2/fr
Publication of WO2012005709A3 publication Critical patent/WO2012005709A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une composition pharmaceutique composée de granules comprenant du valsartan et, éventuellement, des excipients pharmaceutiquement acceptables.
PCT/TR2011/000168 2010-07-05 2011-07-04 Composition pharmaceutique comprenant du valsartan Ceased WO2012005709A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2010/05419A TR201005419A2 (tr) 2010-07-05 2010-07-05 Valsartan içeren farmasötik bileşim.
TR2010/05419 2010-07-05

Publications (2)

Publication Number Publication Date
WO2012005709A2 WO2012005709A2 (fr) 2012-01-12
WO2012005709A3 true WO2012005709A3 (fr) 2012-07-12

Family

ID=44741699

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2011/000168 Ceased WO2012005709A2 (fr) 2010-07-05 2011-07-04 Composition pharmaceutique comprenant du valsartan

Country Status (2)

Country Link
TR (1) TR201005419A2 (fr)
WO (1) WO2012005709A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3342400A1 (fr) * 2016-12-31 2018-07-04 Abdi Ibrahim Ilac Sanayi ve Ticaret A.S. Composition pharmaceutique comprenant de la valsartane et du chlorthalidone

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080293789A1 (en) * 2007-05-24 2008-11-27 Sanovell Ilac Sanayi Ve Ticaret A.S. Valsartan formulations
WO2009022169A1 (fr) * 2007-08-10 2009-02-19 Generics [Uk] Limited Composition de valsartan solide
CN101744813A (zh) * 2010-01-21 2010-06-23 扬子江药业集团有限公司 复方氨氯地平缬沙坦固体制剂及其制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122007000050I1 (de) 1990-02-19 2007-11-08 Novartis Ag Acylverbindungen

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080293789A1 (en) * 2007-05-24 2008-11-27 Sanovell Ilac Sanayi Ve Ticaret A.S. Valsartan formulations
WO2009022169A1 (fr) * 2007-08-10 2009-02-19 Generics [Uk] Limited Composition de valsartan solide
CN101744813A (zh) * 2010-01-21 2010-06-23 扬子江药业集团有限公司 复方氨氯地平缬沙坦固体制剂及其制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 201053, Derwent World Patents Index; AN 2010-J68731, XP002675484 *

Also Published As

Publication number Publication date
WO2012005709A2 (fr) 2012-01-12
TR201005419A2 (tr) 2012-01-23

Similar Documents

Publication Publication Date Title
HK1211475A1 (en) Combination therapy
IL224288A (en) Derivatives of converted pyrazolamide, pharmaceutical preparations containing them and their use
EP2605698A4 (fr) Photopléthysmographie de site central, administration de médicament et sécurité
IL222919A (en) Alcohol-resistant oral form
WO2011093825A3 (fr) Formes posologiques effervescentes comprenant un antibiotique du groupe des céphalosporines
WO2011131943A3 (fr) Compositions pharmaceutiques
WO2012051559A3 (fr) Compositions et méthodes de traitement de l'hypertension artérielle pulmonaire
WO2012007729A3 (fr) Compositions pharmaceutiques
WO2012020097A3 (fr) Utilisation de liants pour la fabrication de formulations stables à l'entreposage
WO2011009938A3 (fr) Stambomycine et dérivés, leur production et leur utilisation comme médicaments
ZA201300241B (en) Pharmaceutical composition comprising amide derivative or pharmaceutically acceptable salt thereof
AU2012280198A8 (en) Darunavir combination formulations
WO2011141488A3 (fr) Compositions pharmaceutiques comprenant de l'hydromorphone et de la naloxone
MX341976B (es) Formulaciones de darunavir.
WO2011126882A9 (fr) Peptides thérapeutiques et leurs dérivés et utilisations thérapeutiques de ceux-ci
WO2014033526A9 (fr) Compositions pharmaceutiques d'étoricoxib
WO2011142731A3 (fr) Formulations comprenant une céphalosporine et un acide clavulanique de troisième génération
ZA201200092B (en) Pharmaceutical compositions and therapeutic methods employing a combination of a manganese complex compound and a non-manganese complex form of the compound
HU1000565D0 (en) Process for the preparation of pharmaceutically active compound and intermediers
WO2011139253A3 (fr) Compositions pharmaceutiques comprenant du ceftibutène
HU1000299D0 (en) Nanostructured atorvastatin, its pharmaceutically acceptable salts and pharmaceutical compositions containing them and process for their preparation
WO2011093828A3 (fr) Formes posologiques solides comprenant du cefprozil
WO2009110010A3 (fr) Forme posologique orale stable
WO2011107921A3 (fr) Composition de milnacipran à libération modifiée
EP2386301A4 (fr) Composition pharmaceutique de lévoamlodipine ou de sels pharmaceutiquement acceptables de celle-ci et de b-bloquants, et son utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11764622

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11764622

Country of ref document: EP

Kind code of ref document: A2